Cargando…
ATM splicing variants as biomarkers for low dose dexamethasone treatment of A-T
BACKGROUND: Ataxia Telangiectasia (AT) is a rare incurable genetic disease, caused by biallelic mutations in the Ataxia Telangiectasia-Mutated (ATM) gene. Treatment with glucocorticoid analogues has been shown to improve the neurological symptoms that characterize this syndrome. Nevertheless, the mo...
Autores principales: | Menotta, Michele, Biagiotti, Sara, Spapperi, Chiara, Orazi, Sara, Rossi, Luigia, Chessa, Luciana, Leuzzi, Vincenzo, D’Agnano, Daniela, Soresina, Annarosa, Micheli, Roberto, Magnani, Mauro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498894/ https://www.ncbi.nlm.nih.gov/pubmed/28679388 http://dx.doi.org/10.1186/s13023-017-0669-2 |
Ejemplares similares
-
Proteomics and transcriptomics analyses of ataxia telangiectasia cells treated with Dexamethasone
por: Menotta, Michele, et al.
Publicado: (2018) -
Ataxia-telangiectasia: A new remitting form with a peculiar transcriptome signature
por: Leuzzi, Vincenzo, et al.
Publicado: (2018) -
Positive effect of erythrocyte-delivered dexamethasone in ataxia-telangiectasia
por: Leuzzi, Vincenzo, et al.
Publicado: (2015) -
Functional Classification of the ATM Variant c.7157C>A and In Vitro Effects of Dexamethasone
por: Biagiotti, Sara, et al.
Publicado: (2021) -
Activation of NRF2 by dexamethasone in ataxia telangiectasia cells involves KEAP1 inhibition but not the inhibition of p38
por: Biagiotti, Sara, et al.
Publicado: (2019)